◈ Nootpedia
Compact view
Research pass: medium Supplement · Capsule SKIP-FOR-NOW MEDIUM

Forskolin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

Mechanism (adenylyl cyclase → cAMP → CREB → BDNF) is real and elegant, but human cognitive RCTs are essentially nonexistent — the LTP/memory story rests on hippocampal slices and rodent models. Body-comp marketing is industry-funded and weakly replicated. Dylan already has better cAMP/BDNF tools planned (bromantane, Semax/Adamax, Cerebrolysin) that come with actual human evidence. Would upgrade to OPTIONAL only if (a) a credible human cognitive RCT emerges, or (b) Dylan develops a specific use case (older relative, glaucoma, etc.).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Mechanism is real, but human cognitive evidence is essentially absent. Dylan's V5 already includes better-evidenced cAMP/BDNF tools (bromantane, Semax/Adamax, Cerebrolysin). Adding forskolin layers cardiovascular side effects (HR, BP) onto an already-stimulant-heavy V5 (modafinil, caffeine ramp, beta-alanine) for unclear benefit. Verdict could shift to OPTIONAL if a credible human cognitive RCT emerged or if Dylan wanted to specifically pilot the Marius protocol after baseline V5 is stable.

  • 30-50, executive maintenance
    OPTIONAL

    (low priority). Same logic; mechanism + safety profile acceptable, evidence still thin. If body-comp recomp matters and they're already overweight, the Godard 2005 trial gives at least a weak positive signal — worth a low-priority 12-week trial with BP/HR monitoring.

  • 50+, mild cognitive decline
    WEAK OPTIONAL

    The cAMP-CREB-BDNF axis is genuinely depleted in aging brains. Forskolin + luteolin is a low-cost, low-risk experiment for users motivated by mechanism. Evidence still thin; would not displace stronger options (donepezil, citicoline, lion's mane, bacopa). Avoid in patients on antihypertensives or anticoagulants without medical supervision.

  • Anxiety-prone
    CAUTION

    Tachycardia and BP changes can amplify anxiety symptoms (somatic anxiety). Skip.

  • High athletic load, tested status (WADA-tested)
    OPTIONAL

    Not on any banned list. Cardiovascular side effects could interfere with high-intensity training (HR drift, BP). If pursuing body-comp angle, run on lighter training days first.

  • Sleep-disordered
    AVOID

    PM dosing. Vasodilation, mild stimulant cardiovascular effect. AM/midday only.

  • Recovery-focused (post-injury, post-illness)
    NEUTRAL

    No specific recovery angle. Anti-inflammatory signaling via cAMP is theoretical; not a primary recovery tool.

  • Strength/anabolic-focused
    OPTIONAL

    (low priority). Some early literature suggests forskolin may modestly raise free testosterone in men (Godard 2005 reported this; replication poor). Mechanism plausibly via cAMP → steroidogenesis in Leydig cells. Effect size small, evidence weak. Not a substitute for diet/training. Not on the WADA list, but anyone in a tested federation should still verify the specific extract label.

▸ Subjective experience (deep)

Most users at 250-500 mg ForsLean (10-20% extract, ~25-100 mg actual forskolin) report subtle to nothing. The closest to a consistent felt effect is mild vasodilation: warm flushing, occasional dizziness on standing (orthostatic), slight nasal congestion, mild "heart-aware" feeling at higher doses. Cognitive felt effects are inconsistent — anyone reporting a sharp pro-cognitive boost from forskolin alone at supplemental doses is most likely placebo or noticing vasodilation/heart-rate change as "stimulation."

With luteolin added (Marius protocol), reports cluster around: mild mental clarity over weeks, occasional vivid dreams, mood lift in some users (consistent with the rolipram-class antidepressant signal at sub-emetic doses). Onset for any cognitive effect is described as cumulative over 1-3 weeks, not acute.

Forskolin's plasma half-life is short (~2 hours oral), Tmax ~30-60 min. Acute vasodilatory / cardiovascular effects appear within an hour and dissipate by 4-6 hours.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown / probably minimal at supplemental doses. Adenylyl cyclase isoform downregulation has been reported with chronic high-dose forskolin in cell culture; clinical relevance at supplemental oral doses unclear. No formal human tolerance study.
  • Recommended cycle: 8-12 weeks on, 4 weeks off is the typical body-comp protocol. For cognitive (Marius) use, 4-12 weeks then break is reasonable. No mandatory cycle on safety grounds; cycling is mostly for cost and to reset any AC-isoform shifts.
  • Reset protocol if needed: Discontinue 4 weeks; expect baseline restoration within 1-2 weeks given short half-life.
▸ Stacking deep dive

Synergistic with

  • luteolin (artichoke leaf extract): The Marius/Romanian protocol. PDE4 inhibition prevents cAMP breakdown, complementing forskolin's cAMP production. Mechanistically coherent; clinical effect in humans unproven.
  • bacopa-monnieri: Both work on memory consolidation via different pathways (bacopa: cholinergic/serotonergic + dendritic remodeling; forskolin: cAMP-CREB-BDNF). No interaction concerns. Bacopa has better human evidence.
  • caffeine (with caution): Caffeine inhibits PDEs at high doses (above typical caffeine intake), so theoretically synergistic for cAMP. Practically, the additive cardiovascular load is the bigger story — tachycardia, BP, jitteriness compound. Dylan's caffeine ramp doesn't pair well with forskolin without HR/BP monitoring.
  • citicoline / alpha-GPC: Acetylcholine substrate; no direct interaction. Complementary to a memory-consolidation thesis. Already in V4.
  • bromantane (theoretical): Both upregulate dopaminergic/BDNF tone via different mechanisms. No data on combination; not contraindicated.

Avoid stacking with

  • PDE4 inhibitors at therapeutic doses (rolipram, roflumilast, apremilast, BPN14770): Direct overlap — forskolin raises cAMP from production side, PDE4 inhibitors raise it from degradation side. Combined cAMP signaling could amplify GI / emetic / cardiovascular side effects. Per the BPN14770 file already on the wiki, this combination is theoretically caution-flagged. Not a typical stack.
  • Antihypertensives (ACE-i, ARBs, beta-blockers, calcium channel blockers, alpha-blockers): Additive blood pressure drop. Not relevant for Dylan but flag for older users.
  • Anticoagulants / antiplatelets (warfarin, DOACs, aspirin, clopidogrel, high-dose fish oil): Additive bleeding risk.
  • Stimulants at high doses (amphetamine, methylphenidate): Additive cardiovascular load (HR, BP).
  • Strong CYP3A4 substrates with narrow therapeutic index: Forskolin has weak CYP3A4 inhibition; clinically modest but theoretical concern.
  • Pre-surgical: Discontinue 1-2 weeks before any surgery (bleeding + BP).

Neutral / safe co-administration

  • All Dylan V4 components: NAC, citicoline, magnesium, fish oil, PS, rhodiola, theanine, glycine/tryptophan, vitamin D, beta-alanine, vitamin C, creatine, curcumin — no concerns at supplemental doses.
  • Modafinil — no specific interaction reported (additive HR/BP plausible at high modafinil doses; minimal at 100 mg).
  • Apigenin (also a CD38 inhibitor + GABA-A modulator + mild CYP inhibitor) — no overlap of mechanism, low interaction risk; some additive CYP3A4 inhibition theoretically.
  • Cerebrolysin, Selank, Semax, Adamax — no overlap, no concern.
▸ Drug interactions deep dive
  • CYP3A4: Mild inhibition reported in vitro. Drugs to watch: statins, midazolam, immunosuppressants, some calcium channel blockers, some chemotherapy. Clinical significance at supplemental doses likely small.
  • CYP2C9: Some inhibition. Warfarin / NSAIDs.
  • P-glycoprotein: Some inhibition.
  • Antihypertensives: Additive (pharmacodynamic, not pharmacokinetic).
  • Anticoagulants: Additive bleeding risk via platelet cAMP elevation.
  • Beta-agonists (asthma): Additive bronchodilation / cardiovascular signaling.
  • Thyroid medication: Theoretical — forskolin stimulates AC in thyroid; clinically not observed in supplemental dosing.
  • Insulin / sulfonylureas: Theoretical hypoglycemia risk via cAMP-mediated insulin release.

For Dylan: not on any of these. Caffeine ramp is the only relevant interaction (additive HR effect) and it's modest.

▸ Pharmacogenomics

Limited pharmacogenomics literature specific to forskolin.

  • CYP3A4/CYP3A5 polymorphisms: Forskolin is a weak CYP3A4 inhibitor and a substrate. Slow metabolizers (CYP3A5 *3 carriers — common in Dylan's Nordic/British ancestry) may have modestly higher exposure. Practical effect minor at supplemental doses.
  • ADRB1 / ADRB2 (β-adrenergic receptor variants): Variants affecting β-adrenergic signaling could in principle modulate the cardiovascular response to forskolin, since the downstream cAMP machinery is shared. Untested clinically.
  • Adenylyl cyclase isoforms (ADCY1-9): No documented variant data on forskolin sensitivity in humans. Different isoforms have different tissue distribution and forskolin sensitivity (AC9 is forskolin-insensitive); polymorphism effects unknown.
  • Once 23andMe results land (~June 2026): check CYP3A5 status. Otherwise no specific forskolin-relevant SNPs to act on.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC supplement Doctor's Best Forskolin (10% standardized, 100 mg) ~$10-15 / 60 caps, ~$5-10/mo high Reputable. Standardized extract. Dose ≈ 10 mg forskolin/cap.
OTC supplement Nature's Way Coleus forskohlii ~$15-25 / 60 caps high Common, easy. Verify standardization (often 10%).
OTC supplement Sabinsa ForsLean — many private-label brands varies high Patented standardized 10% forskolin extract; the form used in Godard 2005. Premium pricing.
OTC supplement CMC Herbal / Indian wholesale 95% pure forskolin varies, cheap medium Higher purity for self-experimenters; verify COA.
OTC supplement Nootropics Depot (when in stock) ~$15-25 / bottle high Typically 20% extract; third-party tested.
OTC supplement iHerb — various brands varies medium-high Easy add to V4 cart if Dylan ever wanted.
Marius stack Forskolin + artichoke leaf extract (luteolin) — separate caps ~$15-25/mo combined high Standard DIY combination. Some products (less common) sell pre-stacked.

Recommendation for Dylan: Don't buy. If he ever changes his mind, Doctor's Best 100 mg (10% standardized) + a luteolin or artichoke leaf product would be the cheapest reasonable pilot.

▸ Biomarkers to track (deep)

If running forskolin (Dylan should not, but for completeness):

  • Baseline (before starting):
    • Resting HR + blood pressure (multiple readings, AM)
    • Body composition (DEXA or at minimum scale + tape)
    • Lipid panel
    • Liver panel (ALT, AST)
    • Estradiol, total + free testosterone (if pursuing strength angle)
    • Fasting glucose / HbA1c
  • During use: Weekly BP/HR for first 4 weeks. Recheck body comp at 6 and 12 weeks. Re-run labs at 12 weeks.
  • Subjective (cheap, daily): Energy, sleep quality, GI symptoms, palpitations, headache, cognitive clarity (if running Marius stack — keep a journal so the placebo bias is at least visible).
  • Post-cycle: Repeat baseline labs at 4 weeks off to check for any persistent shifts (rare).
▸ Controversies / open debates Live debate

  • The Godard 2005 body-comp trial is the entire foundation of forskolin's body-comp marketing. It was funded by Sabinsa (the manufacturer), n=30, and has not been cleanly independently replicated. The Henderson 2005 follow-up in women showed no fat loss. The honest read is "weak signal, possibly real, possibly artifact, dramatically over-marketed." Industry-funded trials with this much commercial leverage and this little independent replication should be downgraded by default.

  • The "long-term potentiation" memory claim is mostly in vitro / animal. Forskolin reliably induces chemical LTP in hippocampal slices and enhances memory consolidation in rodent contextual fear-conditioning, water maze, and novel-object recognition. It is genuinely a textbook tool for studying synaptic plasticity. Translation to human cognitive enhancement at oral supplemental doses has essentially zero RCT support. The "Romanian protocol" / Marius stack has internet credibility, not clinical credibility.

  • Marius / Romanian protocol provenance: The forskolin + artichoke (luteolin) stack is widely attributed to a Reddit/Longecity user "Marius" from the early 2010s. The protocol is not a published research protocol; it's an inferential combination from PDE4 + AC pharmacology. The mechanistic logic is sound, but no controlled trial has tested it. Most reports are anecdotal and confounded by simultaneous racetam / cholinergic stacking.

  • Glaucoma history: Topical forskolin was a real glaucoma drug in the 1980s, then displaced. Some glaucoma researchers continue to argue that forskolin deserves a second look in combination with prostaglandin analogues, but no major drug-development effort is active. This medical history is rarely mentioned by supplement marketers because it doesn't sell fat loss.

  • PDE4 inhibitor side-effect ceiling: The pharmaceutical PDE4 inhibitors that should logically deliver the same memory benefit (rolipram class) are blocked at therapeutic doses by emesis. Forskolin + low-dose luteolin sidesteps that ceiling by being weaker overall, which means the cognitive effect is also weaker. This is the central tradeoff: the OTC version is safer but probably under-dosed for the cognitive endpoint.

  • Why this is a medium-confidence SKIP, not a high-confidence one: The mechanism is real, the safety profile at supplemental doses is acceptable, and it's cheap enough that a 12-week pilot wouldn't be unreasonable. The reason it's a SKIP for Dylan specifically is opportunity cost — his V5 already contains better-evidenced cAMP/BDNF tools, and forskolin's cardiovascular profile pulls in the wrong direction relative to Dylan's caffeine ramp + modafinil + beta-alanine load. For a different user without those tools, the verdict could be a weak OPTIONAL.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW, MEDIUM confidence. Real mechanism, weak human evidence for cognition, body-comp marketing dramatically overstated. Better cAMP/BDNF tools (bromantane, Semax/Adamax, Cerebrolysin) already in Dylan's V5 with stronger human data. Cardiovascular profile (HR, BP) compounds with V5 stimulant load. Would revisit if a credible human cognitive RCT emerges or if Dylan's profile changes (older, recomp-focused, or specific clinical use case).
▸ Open questions / gaps Open
  • No human cognitive RCT of forskolin in healthy adults. Even a 12-week, n=40, double-blind, placebo-controlled trial of forskolin + luteolin vs placebo with cognitive battery (CANTAB, RAVLT, n-back) would settle the central question. This is a striking gap given the mechanism's prominence in synaptic plasticity research.
  • No independent replication of Godard 2005. Body-comp claims hinge on a single industry-funded trial. A non-industry replication would clarify whether the effect is real, artifact, or population-specific.
  • No human PK study comparing standard 10% extract vs 20% vs purified forskolin at matched forskolin doses with cAMP / BDNF measurement.
  • Marius protocol has no controlled trial. Forskolin + luteolin / artichoke at any dose, in any condition, has not been tested in a human RCT for cognitive endpoint.
  • Adenylyl cyclase isoform pharmacogenomics: Different ACs have different forskolin sensitivities (AC9 is largely insensitive). Whether human variation in AC isoform expression / polymorphism predicts forskolin response is unstudied.
  • Long-term safety beyond 12 weeks is not documented in any controlled trial.
▸ Sources (full, with our context)
Back to compact view